Pulse Biosciences (NASDAQ:PLSE) is a bioelectric medicine company focused on developing therapeutic tissue treatment platforms based on its proprietary Nano-Pulse Stimulation (NPS) technology. NPS is a non-thermal technology that delivers nanosecond duration pulses of electrical energy to cells and tissues, targeting cellular structures while sparing surrounding non-cellular tissue. This innovative approach has the potential to benefit various applications in oncology, dermatology, and other fields by inducing immunogenic cell death. Pulse Biosciences aims to leverage its unique technology to provide improved outcomes for patients suffering from a variety of diseases. Grounded in rigorous scientific research, the company is committed to pioneering advancements in bioelectric medicine, with ongoing projects designed to expand the utility and application of its NPS technology to meet pressing clinical needs.